Search

Camizestrant

[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … , and are switched to camizestrant while continuing the same CDK4/6 inhibitor.

Lornoxicam

Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.

Anthrax immune globulin human

to grow and produce anthrax toxins. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

Berdazimer

[A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this … It is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children.

Gadoversetamide

Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

Sibeprenlimab

[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells.

Soy isoflavones

Fencamfamin

It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

Eszopiclone

It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_. … Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia.

Asciminib

Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.